Celsus Therapeutics Plc (CLTX) 36.01

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celsus Therapeutics Plc (CLTX) 36.01 $CLTX

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 98.20 (+1.20), RIGL: 2.51 (+0.22), OCUL: 4.38 (+0.01), AGN: 254.86 (+1.91), SHPG: 194.00 (-0.12), MRK: 58.66 (unch), CLTX: 36.01 (+16.34)

Deerfield Leads Funding in Creation of Akari Therapeutics
PR Newswire - Mon Sep 21, 6:45AM CDT
Deerfield Management Company announced today that it will finance Akari Therapeutics, the new company created through the Celsus Therapeutics Plc (NASDAQ: CLTX) acquisition of Volution Immuno Pharmaceuticals SA. The transaction values the combined company on a fully diluted basis at approximately $150 million.
CLTX: 36.01 (+16.34)

Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Completion of Acquisition and Formation of Complement C5 Inhibitor Company Akari Therapeutics Plc
GlobeNewswire - Fri Sep 18, 6:31AM CDT
Celsus Therapeutics Plc (NASDAQ:CLTX) and Volution Immuno Pharmaceuticals SA today announced that, following shareholder approval obtained at a general meeting of the shareholders of Celsus held on September 16, 2015, the previously announced acquisition by Celsus of Volution has closed. The combined company has changed its name to Akari Therapeutics, Plc and will trade on the NASDAQ Capital Market under the symbol "AKTX" beginning on September 21, 2015. Akari will focus on development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS).
CLTX: 36.01 (+16.34)

4 Small Cap Stocks On The Verge Of A Breakout
ACCESSWIRE - Fri Aug 21, 7:05AM CDT
NEW YORK, NY / ACCESSWIRE / August 21, 2015 / UltimateStockAlerts.com is an exclusive NASDAQ/NYSE Investor Service that alerts undervalued and overlooked trade and investment opportunities. Today we will delve into four stocks that have been showcasing increased volatility combined with unusual volume over the past 24 hours, presenting increased bullish probability to witness potential gains.
T: 43.18 (-0.11), BTU: 2.07 (unch), ACI: 0.58 (-0.25), VGGL: 0.42 (unch), CLTX: 36.01 (+16.34)

Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce $75 Million Private Placement
Marketwired - Tue Aug 18, 6:16AM CDT
Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered into a securities purchase agreement for a private placement with a select group of investors, led by Deerfield, and including Venrock, Vivo Capital, Foresite Capital, New Enterprise Associates, QVT Financial, RA Capital Management and certain other institutional investors.
CLTX: 36.01 (+16.34)

Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Agreement to Create Orphan Disease Company Focused on Complement C5 Inhibition
Marketwired - Mon Jul 13, 6:15AM CDT
Celsus Therapeutics (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a Definitive Exchange Agreement, pursuant to which privately-held Volution Immuno Pharmaceuticals will become a wholly-owned subsidiary of Celsus in an all-stock transaction. The combined company will focus on development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS). Upon closing of the transaction, Celsus expects to be renamed Akari Therapeutics Plc.
CLTX: 36.01 (+16.34)

Allergic Conjunctivitis - Pipeline Review, H1 2015 Includes Late-stage and Discontinued Projects
M2 - Mon Jun 08, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js2p9k/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H1 2015" report to their offering. . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Alcon, Inc. - Allergan, Inc. - Celsus Therapeutics Plc - Eleven Biotherapeutics Inc. - Griffin Discoveries BV - Laila Pharmaceuticals Pvt. Ltd. - NicOx S.A. - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Oxagen Limited - Sun Pharma Advanced Research Company Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/js2p9k/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 254.86 (+1.91), OHRP: 2.73 (unch), CLTX: 36.01 (+16.34), XNCR: 19.35 (+0.41), OCUL: 4.38 (+0.01)

Global Dermatitis Pipeline Review 2015
M2 - Mon Apr 27, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sjwj3/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development - Dermatitis - Therapeutics Assessment - Drug Profiles - Dermatitis - Recent Pipeline Updates - Dermatitis - Dormant Projects - Dermatitis - Discontinued Products - Dermatitis - Product Development Milestones - Appendix Companies Mentioned - Partial List - AlbireoPharma - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Biomar Microbial Technologies - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Celsus Therapeutics Plc - ChemoCentryx, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Circassia Pharmaceuticals plc - Convoy Therapeutics, Inc. - Creabilis SA - Daiichi Sankyo Company, Limited - Dermira Inc. - Eisai Co., Ltd. - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline plc For more information visit http://www.researchandmarkets.com/research/7sjwj3/dermatitis
AQXP: 8.65 (+0.30), FOMX: 8.01 (-0.51), GSK: 45.25 (+0.18), BMY: 76.19 (+1.38), CBPO: 119.55 (+0.17), DERM: 33.20 (-0.36), CCXI: 4.67 (-0.03), ANAC: 99.06 (-0.14), CLTX: 36.01 (+16.34), CELGZ: 1.14 (-0.02)

Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 10.71 (+0.06), FOMX: 8.01 (-0.51), PVCT: 0.28 (-0.01), JNJ: 125.40 (+0.17), DERM: 33.20 (-0.36), ANAC: 99.06 (-0.14), XNCR: 19.35 (+0.41), REGN: 434.00 (+8.88), AQXP: 8.65 (+0.30), BMY: 76.19 (+1.38), GSK: 45.25 (+0.18), VRX.TO: 29.08 (-1.37), CBPO: 119.55 (+0.17), MRK: 58.66 (unch), CCXI: 4.67 (-0.03), CLTX: 36.01 (+16.34), CELGZ: 1.14 (-0.02), NVS: 83.07 (-0.19)

Boston Scientific and Fossil are big market movers
AP - Wed Feb 18, 3:31PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
JACK: 90.69 (+2.30), KNDI: 6.96 (-0.06), FOSL: 31.57 (-0.03), VDSI: 17.02 (+0.31), GT: 28.78 (+0.11), ANGI: 8.15 (+0.06), GOOGL: 800.94 (+9.60), CLTX: 36.01 (+16.34), GOOG: 772.88 (+4.09), YNDX: 21.26 (-0.39)

Celsus Plunges on Dismal Dermatology Drug Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 2:02PM CST
Shares of Celsus Therapeutics (CLTX) fell significantly after the company reported dismal results from a phase II trial on lead pipeline candidate, MRX-6 cream.
LCI: 31.10 (-0.12), SLXP: 172.96 (+0.15), SCMP: 11.89 (+0.14), CLTX: 36.01 (+16.34)

Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint
GlobeNewswire - Tue Feb 17, 6:19AM CST
Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announced today the results from C012013, a Phase II, double-blind, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of MRX-6 cream 2% in a pediatric population with mild to moderate atopic dermatitis. MRX-6 cream did not demonstrate a difference in mean change from baseline to Day 28 in the Investigator's Global Assessment (IGA):
CLTX: 36.01 (+16.34)

Celsus Therapeutics concludes pediatric atopic dermatitis MRX-6 cream 2% enrollment trial
M2 - Wed Jan 14, 6:59AM CST
Biopharmaceutical company Celsus Therapeutics (NasdaqCM:CLTX) disclosed on Tuesday the completion of the enrollment in C012013 trial to evaluate MRX-6 cream 2% in a pediatric atopic dermatitis.
CLTX: 36.01 (+16.34)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 175

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 34

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 16

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 211

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 0

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
Teen Adoption Campaign Makes Room for Mutual Growth

Updated Category News Views 120

A bicycle wobble and a ballet count carry more weight than they first appear to. The new Adoption from Foster Care public service ads put teens in the instructor's spot: a son helps his mother learn to ride a bike in Two Wheeler, while a daughter walks her father through ballet in Routine. It is a small creative reversal, but a smart one. Teen adoption is too often framed...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 0

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading

Top 5 Most Recently Viewed Articles

A.B. Data Appoints Steve Straub as New Operations VP

Updated Category News Views 542

A.B. Data Appoints Steve Straub as New Operations VP A.B. Data, a prominent name in class action notice and claims administration, has elevated Steve Straub to the role of Vice President of Operations. Having served as the Senior Director of Operations since 2023, Steve brings a wealth of experience that will further strengthen the company’s operations. Strategic...

Continue Reading
Conexon Connect Expands Fiber Network for Rural Internet Access

Updated Category News Views 170

Conexon Connect's Milestone Achievement Conexon Connect has successfully completed a transformative fiber-to-the-home (FTTH) project, expanding high-speed internet access to over 12,000 members of rural electric cooperatives. This expansive network marks a significant achievement in bridging the digital divide, particularly for underserved communities. Partnerships...

Continue Reading
Xiaomi MIX Flip 2 Unveils TCL CSOT's Cutting-Edge Displays

Updated Category News Views 349

TCL CSOT Powers the Xiaomi MIX Flip 2's Display Experience TCL CSOT is making waves in the tech world by providing state-of-the-art displays for the Xiaomi MIX Flip 2. This new foldable smartphone marks a significant shift in user experiences, aligning perfectly with the growing demand for portable, high-performance devices. During a recent launch event showcasing...

Continue Reading
Immunic Showcases Promising Results for Vidofludimus Calcium

Updated Category News Views 106

Immunic Highlights Key Findings from CALLIPER Trial Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology company specializing in innovative oral therapies for neurologic and gastrointestinal conditions, recently presented significant data from its Phase 2 CALLIPER trial. This trial evaluates its cornerstone therapy, vidofludimus calcium (IMU-838), aimed at treating...

Continue Reading
Amrop Expands Global Reach with New Office in Colombia

Updated Category News Views 153

Amrop Expands With a New Office in Colombia Amrop, a distinguished global executive search and leadership consulting firm, has recently announced the establishment of a new office in Colombia. This expansion marks a significant milestone for Amrop as they enhance their service offerings in Latin America. Introducing Amrop Colombia Amrop Colombia emerges from the merger...

Continue Reading